Breaking News Instant updates and real-time market news.

CRM

Salesforce

$120.72

-0.28 (-0.23%)

06:06
11/21/18
11/21
06:06
11/21/18
06:06

Salesforce price target lowered to $160 from $190 at Piper Jaffray

Piper Jaffray analyst Alex Zukin lowered his price target for Salesforce to $160 ahead of the company's Q3 results on November 27 and keeps an Overweight rating on the name. A "healthy" demand environment, "strong" execution in multiple verticals, MuleSoft acceleration and a "robust" pipeline heading into the Q4 period support "sustained growth," Zukin tells investors in a pre-earnings research note. The analyst's reduced price target reflects the "meaningful multiple contraction across the sector" but he points out Salesforce is trading below peer averages.

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 06

    Dec

  • 11

    Dec

  • 03

    Mar

CRM Salesforce
$120.72

-0.28 (-0.23%)

10/30/18
NOMU
10/30/18
INITIATION
Target $181
NOMU
Buy
Nomura calls Salesforce core long-term holding, starts with Buy rating
Nomura Instinet analyst Christopher Eberle last night initiated coverage of Salesforce with a Buy rating and $181 price target. The company "dominates" the customer relationship Mmnagement market but has also "planted many seeds" that have helped it become a "dominant go-to platform for digital transformation," Eberle tells investors in a research note. He believes Salesforce's "breadth and depth of products combined with its maniacal customer focus," recurring revenue model, and strategic value to its customers make it a core long-term holding in the software space.
11/19/18
JEFF
11/19/18
NO CHANGE
Target $189
JEFF
Buy
Salesforce expectations for Q3 'seem reasonable,' says Jefferies
Expectations going into Salesforce's Q3 results "seem reasonable" even if the company's internal targets are not hit, Jefferies analyst John DiFucci tells investors in a research note. Further, the analyst believes the 23% consensus billings growth estimate for fiscal Q4 is "certainly achievable." However, Salesforce could guide below expectations to be conservative, which it sometimes does, says DiFucci. The analyst thinks the company remains well positioned to achieve its long-term financial goals and he keeps a Buy rating on the shares with a $189 price target.
11/19/18
DBAB
11/19/18
NO CHANGE
Target $165
DBAB
Hold
Salesforce price target lowered to $165 from $180 at Deutsche Bank
Deutsche Bank analyst Karl Keirstead lowered his price target for Salesforce to $165 ahead of the company's fiscal Q3 results and keeps a Buy rating on the shares. After speaking with several of the company's partners and customers throughout the quarter, the analyst remains comfortable with his rating.
11/20/18
MSCO
11/20/18
NO CHANGE
Target $178
MSCO
Overweight
Salesforce partner checks point to strong finish to FY19, says Morgan Stanley
Morgan Stanley analyst Keith Weiss said his checks with Salesforce partners remain supportive of strong demand across the company's portfolio, leading him to conclude that Salesforce is "well positioned to clear a low Q3 bar." He expects the main focus of the earnings report to be management's guidance for Q4 and preliminary outlook into FY20 given that Weiss views the recent underperformance in Salesforce shares being related to investor concerns about the prospect of a slowdown in enterprise IT spending in 2019, he tells investors. The analyst, who sees Salesforce "firmly on the path" to reaching the high end of management's $21B-$23B target by FY22, keeps an Overweight rating and $178 price target on the stock.

TODAY'S FREE FLY STORIES

TLND

Talend

$49.40

-1.81 (-3.53%)

09:36
03/25/19
03/25
09:36
03/25/19
09:36
Recommendations
Talend analyst commentary  »

Talend price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHI

Robert Half

$63.78

-2.58 (-3.89%)

09:36
03/25/19
03/25
09:36
03/25/19
09:36
Hot Stocks
Breaking Hot Stocks news story on Robert Half »

Robert Half mentioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

09:35
03/25/19
03/25
09:35
03/25/19
09:35
Downgrade
Texas Instruments rating change  »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

09:33
03/25/19
03/25
09:33
03/25/19
09:33
Downgrade
Texas Instruments rating change  »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LNTH

Lantheus

$23.61

-1.575 (-6.25%)

09:33
03/25/19
03/25
09:33
03/25/19
09:33
Hot Stocks
Lantheus promotes John Bolla to COO »

Lantheus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

MEOH

Methanex

$57.73

-2.64 (-4.37%)

09:33
03/25/19
03/25
09:33
03/25/19
09:33
Hot Stocks
M&G Investments announces four director nominees for Methanex board »

M&G Investments, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$41.28

0.75 (1.85%)

09:32
03/25/19
03/25
09:32
03/25/19
09:32
Recommendations
D.R. Horton analyst commentary  »

D.R. Horton benefiting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LNTH

Lantheus

$23.61

-1.575 (-6.25%)

09:31
03/25/19
03/25
09:31
03/25/19
09:31
Hot Stocks
Lantheus announces upcoming retirement of Chief Medical Officer in September »

Lantheus Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

NEON

Neonode

$2.80

(0.00%)

09:28
03/25/19
03/25
09:28
03/25/19
09:28
Hot Stocks
Neonode says Convergence Promotions to act as sales and marketing partner »

Neonode announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLXP

PLx Pharma

$5.54

-0.525 (-8.66%)

09:27
03/25/19
03/25
09:27
03/25/19
09:27
Syndicate
Breaking Syndicate news story on PLx Pharma »

PLx Pharma files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$184.59

-6.555 (-3.43%)

09:26
03/25/19
03/25
09:26
03/25/19
09:26
Hot Stocks
Wex to acquire fuel card business of EG Group »

WEX announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IART

Integra LifeSciences

$55.29

-2.07 (-3.61%)

09:25
03/25/19
03/25
09:25
03/25/19
09:25
Conference/Events
Integra LifeSciences participates in a conference call with JPMorgan »

Medical Supplies &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

PTI

Proteostasis

$4.17

-0.14 (-3.25%)

, VRTX

Vertex

$181.49

-1.07 (-0.59%)

09:25
03/25/19
03/25
09:25
03/25/19
09:25
Recommendations
Proteostasis, Vertex analyst commentary  »

Piper sees 'clear…

PTI

Proteostasis

$4.17

-0.14 (-3.25%)

VRTX

Vertex

$181.49

-1.07 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 10

    Apr

09:25
03/25/19
03/25
09:25
03/25/19
09:25
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

09:25
03/25/19
03/25
09:25
03/25/19
09:25
General news
A Spring Rebound for Producer Sentiment »

A Spring Rebound for…

09:25
03/25/19
03/25
09:25
03/25/19
09:25
Conference/Events
The U.S. Commodity Futures Trading Commission to hold a meeting »

Open Commission Meeting…

ORGS

Orgenesis

$5.01

-0.19 (-3.65%)

09:24
03/25/19
03/25
09:24
03/25/19
09:24
Hot Stocks
Orgenesis to establish new facility for cell, gene therapy manufacturing »

Orgenesis announced plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVP

Avon Products

$3.06

0.28 (10.07%)

09:24
03/25/19
03/25
09:24
03/25/19
09:24
Recommendations
Avon Products analyst commentary at DA Davidson »

Avon Products buyout…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSL

MidSouth Bancorp

$10.22

-0.49 (-4.58%)

09:23
03/25/19
03/25
09:23
03/25/19
09:23
Upgrade
MidSouth Bancorp rating change  »

Sandler O'Neill says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:21
03/25/19
03/25
09:21
03/25/19
09:21
Conference/Events
JPMorgan retail analyst to hold an analyst/industry conference call »

Broadlines &…

PLAN

Anaplan

$38.98

-1.47 (-3.63%)

09:21
03/25/19
03/25
09:21
03/25/19
09:21
Initiation
Anaplan initiated  »

Anaplan initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDOR

Condor Hospitality Trust

$8.70

(0.00%)

09:19
03/25/19
03/25
09:19
03/25/19
09:19
Hot Stocks
Condor Hospitality Trust announces sale of non-core legacy hotel »

Condor Hospitality Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
03/25/19
03/25
09:18
03/25/19
09:18
Options
Overnight activity included 349 trades in SPX and 231 trades in VIX »

349 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTDR

Frontdoor

$32.78

0.38 (1.17%)

09:16
03/25/19
03/25
09:16
03/25/19
09:16
Initiation
Frontdoor initiated  »

Frontdoor initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$79.94

-1.29 (-1.59%)

09:15
03/25/19
03/25
09:15
03/25/19
09:15
Downgrade
AbbVie rating change  »

AbbVie downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 18

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.